Autologous Stem Cell Transplantation in Multiple Myeloma with Renal Failure: Friend or Foe?

Table 4

ASCT in myeloma patients with renal insufficiency: the case report studies.

Author	Year	Country	Age	Immunochemical subtype	Renal function before ASCT	Treatment	Clinical response and renal function after ASCT
Bigé et al. [39]	2009	France	57/56	Case 1: light chain; Case 2: IgA	Case 1: acute renal failure, SCr 673 μmol/l; Case 2: acute renal failure, SCr 576 μmol/l	Case1: ASCT was performed after high-dose melphalan (200 mg/m^2); Case 2: treated with five courses of VAD chemotherapy and then received ASCT	Case 1: SCr 673 μmol/l decreased to 280 μmol/l; Case 2: SCr 576 μmol/l decreased to 450 μmol/l
Lam et al. [38]	2004	China	63	IgA	Normal renal function	Received a non-myeloablative ASCT	Acute renal tubular necrosis
Rebibou et al. [40]	1997	France	49	IgG	Severe renal failure	The therapeutic regimen consisting of one high-dose melphalan infusion and ASCT was infused 5 days after melphalan	CR: 14 months; Renal function: NR
Reiter et al. [37]	1999	Austria	51	Light chain	SCr 1.9 mg/dl	Conventional therapy with VAD, then ASCT infused	CrCl had improved to 46 ml/min; CR: 1 year
Tauro et al. [41]	2002	UK	52	NR	SCr 690 μmol/l	The patient was treated with high-dose melphalan (200 mg/m^2); then ASCT was infused	SCr 690 μmol/l decreased to 429 μmol/l

ASCT: autologous stem cell transplantation; MM: multiple myeloma; SCr: serum creatinine; CrCl: creatinine clearance; CR: complete response; VAD: vincristine, adriamycin, and dexamethasone; NR: not reported.